ILiAD Biotechnologies (ILiAD) is a clinical stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. Their lead candidate is BPZE1, a live attenuated pertussis vaccine.
GPB Scientific is in the business of marketing its proprietary cell separation products to research laboratories, clinical laboratories, and companies in the life science and healthcare fields. These products enable the separation, enrichment, isolation and capture of cells in blood with unprecedented cell yield, viability and purity. GPB's technology addresses major unmet needs in research, diagnostics, therapeutics and disease management.
RenalSense™ is a medical device company dedicated to real-time renal diagnostics.
Improved nerve visualization to reduce risk of nerve damage during surgery.
Seneca Therapeutics, Inc. (Seneca) is pursuing the development of an oncolytic immune-Seneca Valley Virus (SVV) and derivatives as cancer therapeutics, cancer vaccines, and vaccines for infectious diseases.
FORGE Life Science was founded on breakthrough discoveries made at Princeton University. Whereas immuno-oncology drugs engage the patient’s immune system to fight cancer, FORGE antivirals engage the cell’s intrinsic immunity to defend against infection. FORGE’s vision is to develop first-in-class antivirals that are safe, address the problem of acquired drug-resistance, and provide unique broad-spectrum treatment options.
CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care immunotherapy company specializing in blood purification to control deadly inflammation in critically-ill and cardiac surgery patients. The company’s flagship product, CytoSorb®, is approved in the European Union with distribution in 55 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” or “cytokine release syndrome” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis, as well as in cancer immunotherapy.
WuXi PharmaTech is a contract chemistry research and product development services company located in the WaiGaoQiao Free Trade Zone of Shanghai. Founded by a veteran of the US biotechnology industry, WuXi PharmaTech provides customers access to cost-effective world-class medicinal chemistry from a state-of-the-art research chemistry laboratory in Shanghai. The company's current customers include fourteen of the world's twenty largest pharmaceutical companies as well as dozens of prominent biotech companies. WuXi PharmaTech's laboratories are equipped with state-of-the-art instrumentation operated by experienced scientists to ensure high throughput synthesis combined with tight quality control and precise analysis. The company conducts custom synthesis, process research, scale up services and bulk synthesis of pharmaceutical intermediates.
WuXi is traded on the NYSE under the ticker symbol WX.
Callidus Biopharma, Inc, is a development-stage biotechnology company focused on developing superior follow-on biologic drugs (improved biosimilars or "biobetters"). The Company has used its deep understanding of enzyme replacement therapies (ERTs) for lysosomal storage disorders (LSDs) to create novel classes of molecules with new intellectual property, among which is a lead drug candidate for the treatment of Gaucher disease and a lead drug candidate for the treatment of Pompe disease.
Callidus was acquired by Amicus Therapeutics (NASDAQ: FOLD) in November 2013.
Advanced BioHealing, Inc. is a biomedical company commercializing products based on its proprietary cell culture and tissue preservation technologies. Celaderm™, the Company's lead product, represents a significant step forward in advanced wound care technology: it is the first clinically effective cell-based wound dressing that is inexpensive to produce and capable of being stored in a conventional freezer ready for immediate use. Advanced BioHealing was acquired for $750M in cash by Shire Pharmaceuticals in July 2011 as the base on which to build Shire's regenerative medicine business.
Lerner Medical Devices, Inc. has developed a proprietary medical device to treat scalp psoriasis, a widespread chronic skin disease affecting approximately 3.8 million people in the U.S. and over 7.5 million globally. The High Intensity Fiber Optic Light (HIFOL) LiteBrush™ delivers therapeutic light through optical fibers, offering decisively superior results over any other treatment modality on the market today, including pills, injectables or topicals, with minimal side effects and lower overall cost. The LiteBrush™ system is FDA cleared and patented.
Core Essence Orthopaedics creates innovative products that help perfect high-volume, sports medicine procedures involving soft tissue and skeletal repair of the extremities. The company's products better enable surgeons to perform minimally invasive arthroscopic and endoscopic procedures, leading to higher success rates and lower recovery times.
The intuitive product portfolio of Core Essence Orthopaedics is utilized by hospitals and surgery centers across the nation.
MedAvante's Centralized Expert Ratings Services is a unique service based on the recognition that psychological assessments are the most important component of the clinical trial for mental illness therapeutics, establishing the foundation upon which the study rests. MedAvante's approach improves signal detection for CNS trials by centralizing psychometric assessments in the hands of fewer expert rates via high resolution video-conferencing and telephone. Centralizing the assessments increases the accuracy, reliability and quality of the psychiatric diagonstic and symptom assessments. This can:
The net effect:
MedAvante's Centralized Expert Ratings Services provide pharmaceutical companies with faster, more certain decision making regarding CNS drugs.
Hygeia Therapeutics, Inc. is an emerging specialty pharmaceutical company focused on the development of topical products for large under-served markets in women's healthcare and dermatology. The Company's technology creates so-called "soft" modulators of estrogen and androgen hormone receptors.
In September 2013, Hygeia and Hygeia spin-out, Canterbury Laboratories, were acquired by Stratus Media Group, Inc. (OTCQB:SMDI)
Pharmacopeia Drug Discovery, Inc. was a publicly traded (NASDAQ: PCOP) chemistry-based collaborative drug discovery company, focused on the creation of small molecule therapeutics. Pharmacopeia was acquired by Ligand Pharmaceuticals (NASDAQ: LGND) in 2008.
PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms.
QuantumBio, Inc is accelerating the drug discovery efforts by providing pharmaceutical, biotechnology companies and life science research organizations a next generation of Computer-Assisted Molecular Modeling (CAMM) and Computer-Assisted Drug Design (CADD) solutions.
Azure Therapeutics is a seed stage that has developed a proprietary topical non-antihistamine, non-steroidal product for the relief of chronic itch.